For the second time in three weeks I'm at a flu vaccine manufacturing plant today. Construction isn't finished on the Novartis site yet, but nonetheless they're doing the formal ribbon-cutting ceremony here in Holly Springs, NC this afternoon.    Read More

Stocks slid Tuesday morning, after soaring to new 2009 highs on Monday, as a report showed the economy grew less than expected in the third quarter. Douglas Roberts, founder and chief investment strategist at Channel Capital Research.com, and Dean Barber, founder and president of Barber Financial Group, shared their views.   Read More

With the health care debate continuing, how can investors make money in the sector? Barbara Ryan, managing director and senior pharmaceuticals analyst at Deutsche Bank Securities, and Charles Boorady, health care providers analyst at Citigroup, shared their insights.   Read More

Before everyone gets their underwear in a bundle, the Senate merely voted to start the debate and amendment process for the Reid Health Care bill.    Read More

The axle that is health care reform, and around which Washington is wrapped, threatens to scuttle the Presidents domestic agenda while he frustratingly tries to reach out to foreign allies (or non allies as the case may be).   Read More

In U.S. President Barack Obama's speech to Asia-Pacific leaders at the APEC Summit in Singapore over the weekend, he highlighted the importance of a strong China economy in the context of global growth.   Read More

It was an extraordinary sight: Warren Buffett and Bill Gates walking around the Columbia University campus in Manhattan with CNBC's Becky Quick, and three TV cameras.  During the tour, Buffett and Gates answered Becky's questions on a wide variety of topics.  Here, for the first time in a CNBC.com exclusive, is the complete Buffett-Gates 'Columbia Walk and Talk.'   Read More

Following health care reform is kind of like trying to drive in England. Confusing as all heck for most Americans.   Read More

Investors, patients and activists, no doubt, hope they won't have to put out a mayday distress call, but as Dendrama's fate would have it, the company announced today that the Food and Drug Administration has assigned May Day as its decision day for the prostate cancer treatment Provenge.   Read More

Earlier this week I reported that Dr. Allen Taylor who ran the Abbott vs. Merck cholesterol drug study, which Abbott's drug Niaspan won, would only say that ABT has paid him more than $10,000 in lecture and consulting fees. But he wouldn't be any more specific than that.    Read More